Previous close | 8.35 |
Open | 8.32 |
Bid | 8.39 x 1000 |
Ask | 8.40 x 3100 |
Day's range | 8.31 - 8.42 |
52-week range | 7.70 - 8.99 |
Volume | |
Avg. volume | 5,710,767 |
Market cap | 38.333B |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | 29.98 |
EPS (TTM) | 0.28 |
Earnings date | N/A |
Forward dividend & yield | 0.21 (2.55%) |
Ex-dividend date | 14 Mar 2024 |
1y target est | 9.63 |
Key Insights Using the 2 Stage Free Cash Flow to Equity, Haleon fair value estimate is UK£2.62 Haleon is estimated to...
AstraZeneca (AZN) is set to acquire Fusion Therapeutics (FUSN). Pfizer (PFE) plans to sell some shares of Haleon to lower stake from 32% to 24%.
Strong sales growth of GSK's specialty drugs and vaccines, the contribution from new products and positive pipeline updates should drive the stock in the future quarters.